Prevention of insulin-dependent diabetes: Where are we now?

Diabetes/Metabolism Reviews

Volumn 12, Issue 2, 1996, Pages 127-135

  Pozzilli, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ANTIOXIDANT; COLECALCIFEROL DERIVATIVE; INSULIN; NICOTINAMIDE;

DIET; HEREDITY; HUMAN; IMMUNIZATION; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029761023     PISSN: 07424221     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0895(199607)12:2<127::AID-DMR160>3.0.CO;2-8     Document Type: Review

References (48)

1. Akerblom HK, Savilahti E, Saukkonen TT, Paganus A, Virtanen SM, Terami K, Knip M, Ilonen J, Reijonen H, Karjalainen J, Vaarala O, and Reunanen A: The case for elimination of cow's milk in early infancy in the prevention of type 1 diabetes: the Finnish experience. Diabetes Metab Rev 9: 269-278, 1993.
2. Feutren G, Assan R, and Karsentry G: Cyclosporin increases the rate and length of remission in insulin dependent diabetes of recent onset. Lancet ii: 119, 1986.
3. Canadian European randomized Control Trial Group (CERCTG): Cyclosporin induced remission of IDDM. Diabetes 37: 1574, 1988.
4. Klein R, Kelin BEK, and Moss SE: The Wisconsin Epidemiologic study of diabetic retinopathy. Diabetes 44: 796-801, 1995.
5. Atkinson MA, and Maclaren NK: Mechanisms of the disease: the pathogenesis of insulin dependent diabetes mellitus. N Engl J Med 331: 1428-1436, 1994.
6. Davies JL, Kawaguchi Y, Bennett ST, Copeman JB, Cordell HJ, Pritchard LE, Reed PW, Cough SCL, Jenkins SC, Palmer SM, Balfour KM, Rowe BR, Farrall M, Barnett AH, Bain SC and Todd JA: A genome wide search for human type 1 diabetes susceptibility genes. Nature 371: 130-136, 1994.
7. Karjalainen J, Martin JM, Knip M, Ilonen J, Robinson SH, Savilahti E, Akerblom HK, and Dosch HM: A bovine albumin peptide as a possible trigger of insulin dependent diabetes mellitus. N Engl J Med 327: 302-307, 1992.
8. Wasmuth HE, Becker F, Seebaum S, Elliott RB, and Federlin K: Association of antibodies to β casein with type 1 diabetes. Autoimmunity 21: A328, 1995.
9. Bodington M, McNally PG, and Burden AC: Cow's milk and type 1 childhood diabetes: no increase in risk. Diabetic Med 11: 663-665, 1994.
10. Patterson CC, Carson DJ, Hadden DR, Waugh NR, and Cole SK: A case-control investigation of perinatal risk factors for childhood IDDM in Northern Ireland and Scotland. Diabetes Care 17: 376-381, 1994.
11. Dahl-Jorgenesen K, Joner G, and Hanssen KF: Relationship between cow's milk consumption and incidence of IDDM in childhood. Diabetes Care 14: 1081-1083, 1991.
12. Kostraba JN: What can epidemiology tell us about the role of infant diet in the etiology of IDDM? Diabetes Care 17: 87-91, 1994.
13. Fava D, Leslie RDG, and Pozzilli P: Relationship between dairy product consumption and incidence of IDDM in childhood in Italy. Diabetes Care 17: 1488-1490, 1994.
14. Okamoto H. In Molecular Biology of the Islets of Langerhans, Okamoto H (Ed). Cambridge University Press, Cambridge, 1990, pp. 418-422.
15. Pipeleers D, and van De Winkel M: Pancreatic B cells possess defense mechanisms against cell-specific toxicity. Proc Natl Acad Sci USA 83: 5267-5271, 1986.
16. Burkart V, Koike T, Brenner HH, and Kolb H: Oxygen radicals generated by the enzyme xanthine oxidase lyse rat pancreatic islet cells in vitro. Diabetologia 35: 1028-1034, 1992.
17. Kallman B, Burkart V, Kroncke KD, Kolb-Baclofen V, and Kolb H: Toxicity of chemically generated nitric oxide towards pancreatic islet cell can be prevented by nicotinamide. Life Sci 51: 671-678, 1992.
18. + depletion. Biochem Biophys Res Commun 199: 1270-1277, 1994.
19. Cetkovic-Cvrlje M, Sandier S, and Eizirik DL: Nicotinamide and dexamethasone inhibit IL-1 induced nitric oxide production by RINm5F cells without decreasing mRNA expression for nitric oxide synthase. Endocrinology 133: 1739-1743, 1993.
20. Andersen HU, Jorgensen KH, Egeberg J, Mandrup-Poulsen T, and Nerup J: Nicotinamide prevents interleukin-1 effects on accumulated insulin release and nitric oxide production in rat islets of Langerhans. Diabetes 43: 770-777, 1994.
21. Eizirik DL, Sandler S, Wlesh N, Bendtzen K, and Hellerstrom C: Nicotinamide decreases nitric oxide production and partially protects human pancreatic islets against the suppressive effects of combinations of cytokines. Autoimmunity 19: 193-198, 1994.
22. Yamada K, Miyajima E, and Nonaka K: Inhibition of cytokine-induced MHC class II but not class I molecule expression on mouse islet cells by nicotinamide and 3-aminobenzamide. Diabetes 39: 1125-1130, 1990.
23. Pozzilli P, and Andreani D: Nicotinamide, a vitamin with the potential to prevent type 1 diabetes. Diabetes Metab Rev 9: 219-230, 1993.
24. Elliott RB, and Chase HP: Prevention or delay of type 1 (insulin-dependent) diabetes in children using nicotinamide. Diabetologia 34: 362-366, 1991.
25. Herskowitz RD, Jackson RA, Soeldner JS, and Eisenbarth GS: Pilot trial to prevent type 1 diabetes: progression to overt IDDM despite oral nicotinamide. Autoimmunity 2: 733-737, 1989.
26. Palmer JP, and McCulloch DK: Prediction and prevention of IDDM. Diabetes 40: 943-947, 1991.
27. Hagopian WA, Sanjeevi CB, Kockum I, Landinolsson M, Karlsen AE, Sunkvist G, Dahlquist G, Palmer J, and Lernmark A: Glutamate decarboxylase, insulin and islet cell antibodies and HLA typing detect diabetes in a general population-based study of Swedish children. J Clin Invest 95: 1505-1511, 1995.
28. Pozzilli P, Browne PD, Kolb H, and the Nicotinamide Trialists: Meta-analysis of nicotinamide treatment in patients with recent onset insulin dependent diabetes. Diabetes Care in press.
29. Vlahos WD, Seemayer TA, and Yale JF: Diabetes prevention in BB rats by inhibition of endogenous insulin secretion. Metabolism 40: 825-829, 1991.
30. Atkinson MA, Maclaren NK, and Luchetta R: Insulitis and insulin dependent diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 39: 933-937, 1990.
31. Peakman M, Hussain MJ, Millward BA, Leslie RDG, and Bargani D: Effect of initiation of insulin therapy on T-lymphocyte activation in type 1 diabetes. Diabetic Med 7: 327-330, 1990.
32. Aaen K, Rygard J, Josenson K, Petersen H, Brogren CH, Horn T, and Buschard K: Dependence of antigen expression on functional state of cells. Diabetes 39: 697-701, 1990.
33. Shah SC, Malone IL, and Simpson NE: A randomized trial of intensive therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 320: 550-554, 1989.
34. Keller RJ, Eisenbarth GS, and Jackson RA: Insulin prophylaxis in individuals at high risk of type 1 diabetes. Lancet 341: 927-928, 1993.
35. Thompson HSG, and Staines NA: Could specific oral tolerance be a therapy for autoimmune disease? Immunol Today 11: 396-399, 1990.
36. Shizuru JA, Edwards-Taylor C, Banks B, Gregory AK, and Fathman CG: Immunotherapy of the non-obese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science 240: 659-666, 1988.
37. + T lymphocytes. J Immunol 142: 748-752, 1989.
38. Zhang I, Davidson L, Eisenbarth G, and Weiner HL: Suppression of diabetes in non-obese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 88: 10252-10256, 1991.
39. Miller AM, Lider O, and Weiner HL: Antigen-driven bystander suppression after oral administration of antigens. J Exp Med 174: 791-798, 1991.
40. Elliott JF, Qin HY, Bhatti S, Smith DK, Singh RK, Dillon T, Lauzon J, and Singh B: Immunization with the larger isoform of mouse glutamic acid decarboxylase (GAD67) prevents autoimmune diabetes in NOD mice. Diabetes 43: 1494-1499, 1994.
41. Friedman A, and Weiner HL: Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc Natl Acad Sci USA 91: 6688-6692, 1994.
42. Weiner HL, Friedman A, Miller A, Khourty SJ, Al-Sabbagh A, Santos L, Sayegh M, Nussenblatt RB, Trentham DE, and Hafler DA: Oral tolerance: Immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 12: 809-837, 1994.
43. Weiner H, Mackin GA, Matsui M, Orav EJ, Khoury SJ, Dawson DM, and Hafler DA: Double blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259: 1321-1324, 1993.
44. Trentham D, Dynesius-Trentham R, Orav E, Combitchi D, Lorenzo C, Sewell KL, Hafler DA, and Weiner HL: Effects of oral administration of collagen on rheumatoid arthritis. Science 261: 1727-1730, 1993.
45. Muir A, Peck A, Clare-Salzler M, Song YH, Cornelius J, Luchetta R, Krischer J, and Maclaren NK: Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intra islet interferon-gamma transcription. J Clin Invest 95: 628-634, 1995.
46. Zhang JZ, Davidson I, Eisenbarth G, and Weiner HL: Suppression of diabetes in non obese diabetic mice by oral administration of porcine insulin. J Endocrinol Invest 17: 573, 1994.
47. Wegmann DR, Gill RG, Norbury-Glasen M, Schlott N, and Daniel D: Analysis of the spontaneous T cell response to insulin in NOD mice. J Autoimmun 7: 833-843, 1994.
48. Brocke S, Gijbels K, Allegretta M, Ferber I, Piercy C, Blankenstein T, Martin R, Utz U, Karin N, Mitchell D, Veromaa T, Waisman A, Gaur A, Conion P, Ling N, Fairchild PJ, Wraith DC, O'Garra A, Fathman CG, and Steinman L: Treatment of experimental encephalomyelitis with peptide analogue of lyelin basic protein. Nature 379: 343-346, 1996.